Description | FUNCTION:Probablyinvolvedinformationofautophagosomalvacuoles(autophagosomes).SUBUNIT:3differentlightchains,LC1,LC2andLC3,canassociatewithMAP1AandMAP1Bproteins.SUBCELLULARLOCATION:LC3-I:Cytoplasm.LC3-II:Intracytoplasmicmembrane;lipid-anchor.LC3-IIbindstotheautophagicmembranes.TISSUESPECIFICITY:Mostabundantinplacenta,lungandovary.PTM:TheprecursormoleculeiscleavedbyAPG4B/ATG4Btoformthecytosolicform,LC3-I.ThisisactivatedbyAPG7L/ATG7,transferredtoATG3andconjugatedtophospholipidtoformthemembrane-boundform,LC3-II.SIMILARITY:BelongstotheMAP1LC3family. |
BatchNo. | Seeproductlabel |
Unitsize | 100µl |
Antigen | Asyntheticpeptide(CQEEVAGIRAKF)correspondingtotheN-terminalofhumanMAP1LC3CconjugatedtoBlueCarrierProteinhasbeenusedastheimmunogen.ThepeptideishomologouswiththecorrespondingsequencederivenfromMAP1LC3CproteininMacacamulatta(monkey)andCanisfamiliaris(dog). |
OtherNames | Microtubule-associatedproteins1A/1Blightchain3C;Microtubule-associatedprotein1lightchain3gamma;MAP1A/MAP1BLC3C;MAP1A/1Blightchain3C;MAP1lightchain3-likeprotein3;Autophagy-relatedproteinLC3C;Autophagy-relatedubiquitin-likemodifierLC3C;APG8c;MAP1LC3C |
Accession | MLP3C_HUMAN |
Producedin | Rabbit |
Purity | Wholeserum |
Applications | IHC,immunofluorescence,WB.Adilutionof1:100to1:1000dilutionisrecommendedfortheseapplications.Biosensisrecommendsoptimaldilutions/concentrationsshouldbedeterminedbytheenduser. |
Specificity | IHCandWBconfirmedthespecificityforMAP1LC3C.ThisantibodyshouldrecogniseMAP1LC3ConlyandnottheotherformsMAP1LC3AandMAP1LC3B. |
Cross-reactivity | Human,otherspecieshavenotyetbeentested. |
Form | Lyophilised |
Reconstitution | Reconstitutein100µlofsterilewater.Centrifugetoremoveanyinsolublematerial. |
Storage | Afterreconstitutionkeepaliquotsat-20ºCforahigherstABIlity,andat4ºCwithanappropriateantibacterialagent.Glycerol(1:1)maybeaddedforanadditionalstability.Avoidrepetitivefreeze/thawcycles. |
ExpiryDate | 12monthsafterpurchase |
References | 1.GreenbergJT.DevCell.8(6):799-801.(2005) 2.BaehreckeEH.NatRevMolCellBiol.6(6):505-10.(2005) 3.LevineB.Cell.120(2):159-62.(2005) 4.TanidaI.,etal.J.Biol.Chem.279:36268-36276(2004) 5.LumJJ,etal.NatRevMolCellBiol.6(6):439-48.(2005) 6.TanidaI.,etal.Int.J.Biochem.CellBiol.36:2503-2518(2004) |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。